Wharton S et al. (2019) Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery. Clinical Obesity 9:e12323. doi: 10.1111/cob.12323.
The authors would like to advise readers on an update to the funding information as detailed below:
CONFLICTS OF INTEREST
S.W. is the Medical Director of the Wharton Medical Clinic, and an internal medicine specialist with privileges at Toronto East General Hospital, and Hamilton Health Sciences. S.W. has received payment in the past from Novo Nordisk, Eli Lilly, Janssen, and Astra Zeneca for advisory work. J.L.K. has received funding in the past in the form of research grants from CIHR (#131594). E.K. is currently employed as the Research Coordinator at the Wharton Medical Clinic. R.A.G.C. was previously employed as the Research Coordinator at the Wharton Medical Clinic and is working with Novo Nordisk on research publications. M.L. has no conflicts of interests to report. Novo Nordisk has financially supported the journal fees for this publication. The authors take full responsibility for the content and conclusions stated in this manuscript. Novo Nordisk neither influenced the content of this publication nor was it involved in the study design, data collection, analysis, interpretation or review.